The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with generalized myasthenia gravis.
Sign informed consent form;
Subjects with generalized myasthenia gravis;
Serum AchR(Acetylcholine receptor)-Ab or MUSK-Ab was positive during screening;
MG-ADL ≥5 at screening and baseline;
Subjects with MGFA I and V type;
Subjects usingprescribed drugs;
Subjects with a prescribed disease or history of disease;
The subjects has prescribed examination abnormalities that are assessed as unsuitable for participation in the study by the investigator;
Shanghai Jiaolian Drug Research and Development Co., Ltd
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Collaborator